Download MendeleyThe discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang, H.L., Cee, V.J., Chavez, F., Lanman, B.A., Reed, A.B., Wu, B., Guerrero, N., Lipford, J.R., Sastri, C., Winston, J., Andrews, K.L., Huang, X., Lee, M.R., Mohr, C., Xu, Y., Zhou, Y., Tasker, A.S.(2015) Bioorg Med Chem Lett 25: 834-840
- PubMed: 25597005
- DOI: https://doi.org/10.1016/j.bmcl.2014.12.068
- Primary Citation of Related Structures:
4RPV, 4WRS - PubMed Abstract:
The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to tumorigenesis. As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Herein, we describe our efforts toward the development of a potent, pan-Pim inhibitor. The synthesis and hit-to-lead SAR development from a 3-(pyrazin-2-yl)-1H-indazole derived hit 2 to the identification of a series of potent, pan-Pim inhibitors such as 13o are described.
Organizational Affiliation:
Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA. Electronic address: huiw@amgen.com.
